{"id":28350,"date":"2023-07-17T15:56:22","date_gmt":"2023-07-17T20:56:22","guid":{"rendered":"https:\/\/myeloma.ca\/?page_id=28350"},"modified":"2026-04-10T13:05:43","modified_gmt":"2026-04-10T18:05:43","slug":"formation-medicale-continue-pour-les-fournisseurs-de-soins-primaires","status":"publish","type":"page","link":"https:\/\/myeloma.ca\/fr\/professionnels-de-la-sante\/formation-medicale-continue-pour-les-fournisseurs-de-soins-primaires\/","title":{"rendered":"Formation m\u00e9dicale, outils cliniques et \u00e9v\u00e9nements"},"content":{"rendered":"<div class=\"page-intro-block   block_7742e6ae3270f61c8f2a8b623b80dad5\">\n    <div class=\"container\">\n        <div class=\"left-content\">\n            <div class=\"content\">\n                <h1><strong class='second-font-family is-italic is-italic-fw'>Formation m\u00e9dicale,<\/strong> outils cliniques et \u00e9v\u00e9nements<\/h1>\n            <\/div>\n            <div class=\"bottom-content\">\n                <div class=\"actions-btns-wrapper\">\n                    <a class=\"print-btn\" href=\"#\">\n                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"13.545\" height=\"14.195\" viewBox=\"0 0 13.545 14.195\"><path d=\"M13.786,9.785v-2.6H7.759v2.6H6.743V6H14.8V9.785Zm-8.77,1.183h0Zm10.142,1.873a.457.457,0,0,0,.356-.177.639.639,0,0,0,0-.828.445.445,0,0,0-.711,0,.639.639,0,0,0,0,.828A.457.457,0,0,0,15.158,12.841Zm-1.371,6.171V15.227H7.759v3.785ZM14.8,20.2H6.743v-3.47H4v-4.85a2.2,2.2,0,0,1,.516-1.489,1.619,1.619,0,0,1,1.278-.6H15.75a1.619,1.619,0,0,1,1.278.6,2.2,2.2,0,0,1,.516,1.489v4.85H14.8Zm1.727-4.653V11.875a.963.963,0,0,0-.22-.651.7.7,0,0,0-.559-.256H5.795a.7.7,0,0,0-.559.256.963.963,0,0,0-.22.651v3.667H6.743v-1.5H14.8v1.5Z\" transform=\"translate(-4 -6)\" fill=\"#3e3a3b\"\/><\/svg>\n                        <span>Imprimer<\/span>\n                    <\/a>\n                    <a class=\"share-btn\" href=\"mailto:?subject=I wanted you to see this!&amp;body=https:\/\/myeloma.ca\/fr\/professionnels-de-la-sante\/formation-medicale-continue-pour-les-fournisseurs-de-soins-primaires\/\">\n                        <svg height=\"14.195\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 512 512\"><path d=\"M64 96c-17.7 0-32 14.3-32 32v39.9L227.6 311.3c16.9 12.4 39.9 12.4 56.8 0L480 167.9V128c0-17.7-14.3-32-32-32H64zM32 207.6V384c0 17.7 14.3 32 32 32H448c17.7 0 32-14.3 32-32V207.6L303.3 337.1c-28.2 20.6-66.5 20.6-94.6 0L32 207.6zM0 128C0 92.7 28.7 64 64 64H448c35.3 0 64 28.7 64 64V384c0 35.3-28.7 64-64 64H64c-35.3 0-64-28.7-64-64V128z\"\/><\/svg>\n                        <span>Partager<\/span>\n                    <\/a>\n                <\/div>\n                <div class=\"lb-breadcrumb\">\n                    <div class=\"lb-breadcrumbs\"><span><a href=\"https:\/\/myeloma.ca\/fr\/\">Accueil<\/a><\/span><span class=\"lb-breadcrumb-separator\"> | <\/span><\/div>                <\/div>\n            <\/div>\n\n        <\/div>\n    <\/div>\n    <div class=\"page-intro-image-wrapper\">\n\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1707\" src=\"https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/51071131967_f4106d393a_o-scaled.jpg\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/51071131967_f4106d393a_o-scaled.jpg 2560w, https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/51071131967_f4106d393a_o-300x200.jpg 300w, https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/51071131967_f4106d393a_o-1024x683.jpg 1024w, https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/51071131967_f4106d393a_o-768x512.jpg 768w, https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/51071131967_f4106d393a_o-1536x1024.jpg 1536w, https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/51071131967_f4106d393a_o-2048x1365.jpg 2048w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>    <\/div>\n        <div class=\"left-content mobile\">\n            <div class=\"bottom-content\">\n                <div class=\"actions-btns-wrapper\">\n                    <a class=\"print-btn\" href=\"#\">\n                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"13.545\" height=\"14.195\" viewBox=\"0 0 13.545 14.195\"><path d=\"M13.786,9.785v-2.6H7.759v2.6H6.743V6H14.8V9.785Zm-8.77,1.183h0Zm10.142,1.873a.457.457,0,0,0,.356-.177.639.639,0,0,0,0-.828.445.445,0,0,0-.711,0,.639.639,0,0,0,0,.828A.457.457,0,0,0,15.158,12.841Zm-1.371,6.171V15.227H7.759v3.785ZM14.8,20.2H6.743v-3.47H4v-4.85a2.2,2.2,0,0,1,.516-1.489,1.619,1.619,0,0,1,1.278-.6H15.75a1.619,1.619,0,0,1,1.278.6,2.2,2.2,0,0,1,.516,1.489v4.85H14.8Zm1.727-4.653V11.875a.963.963,0,0,0-.22-.651.7.7,0,0,0-.559-.256H5.795a.7.7,0,0,0-.559.256.963.963,0,0,0-.22.651v3.667H6.743v-1.5H14.8v1.5Z\" transform=\"translate(-4 -6)\" fill=\"#3e3a3b\"\/><\/svg>\n                        <span>Imprimer<\/span>\n                    <\/a>\n                    <a class=\"share-btn\" href=\"mailto:?subject=I wanted you to see this!&amp;body=https:\/\/myeloma.ca\/fr\/professionnels-de-la-sante\/formation-medicale-continue-pour-les-fournisseurs-de-soins-primaires\/\">\n                        <svg height=\"14.195\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 512 512\"><path d=\"M64 96c-17.7 0-32 14.3-32 32v39.9L227.6 311.3c16.9 12.4 39.9 12.4 56.8 0L480 167.9V128c0-17.7-14.3-32-32-32H64zM32 207.6V384c0 17.7 14.3 32 32 32H448c17.7 0 32-14.3 32-32V207.6L303.3 337.1c-28.2 20.6-66.5 20.6-94.6 0L32 207.6zM0 128C0 92.7 28.7 64 64 64H448c35.3 0 64 28.7 64 64V384c0 35.3-28.7 64-64 64H64c-35.3 0-64-28.7-64-64V128z\"\/><\/svg>\n                        <span>Partager<\/span>\n                    <\/a>\n                <\/div>\n            <\/div>\n        <\/div>\n    <\/div>\n\n<div class=\" content-1-block   block_482170a52668bc77be859b42835080b8  \" style=\"padding-top: var(--wp--preset--spacing--70);padding-bottom: var(--wp--preset--spacing--70);\">\n    <div class=\"container\">\n\t\t        <div class=\"content\">\n\t\t\t<h2>Formation m\u00e9dicale, outils cliniques et \u00e9v\u00e9nements<\/h2>\n<p>My\u00e9lome Canada favorise l&rsquo;acc\u00e8s \u00e0 la formation m\u00e9dicale fond\u00e9e sur des donn\u00e9es probantes pour les professionnels de la sant\u00e9 qui participent \u00e0 la prise en charge des personnes atteintes d\u2019un my\u00e9lome. Cette section regroupe des programmes de formation fiables con\u00e7us par des fournisseurs de formation m\u00e9dicale continue.<\/p>\n<p>Notre objectif est d\u2019offrir \u00e0 l\u2019ensemble des professionnels de la sant\u00e9 une formation pratique et \u00e0 jour qui am\u00e9liore le d\u00e9pistage pr\u00e9coce, facilite le r\u00e9f\u00e9rencement des patients vers les services appropri\u00e9s et soutient l&rsquo;administration s\u00e9curitaire de traitements novateurs dans divers milieux de soins.<\/p>\n<p>Consultez les onglets ci-dessous pour acc\u00e9der \u00e0 des programmes de formation, des modules d&rsquo;auto\u00e9valuation, des outils cliniques et des \u00e9v\u00e9nements.<\/p>\n        <\/div>\n    <\/div>\n<\/div>\n\n<div class=\" content-1-block   block_5f23f9acec9f39552ff0b62376e1918a  \" style=\"\">\n    <div class=\"container\">\n\t\t        <div class=\"content\">\n\t\t\t        <\/div>\n    <\/div>\n<\/div>\n\n<div class=\"master-tabs-block   block_cb687a9e1be93955aca345e2a2a2691e  \">\n    <div class=\"container\">\n        <div class=\"tab-selector-wrapper\">\n        <\/div>\n    <\/div>\n    <div class=\"acf-innerblocks-container\">\n<div data-tab-name=\"Soins primaires\"\n     id=\"soins-primaires\"\n     class=\"master-tab-block m-pt0  block_6ba274bb14bf31c2b3f9869d8064ae01\">\n    <div class=\"lm-tab-content\">\n        <div class=\"acf-innerblocks-container\">\n<div class=\" content-1-block m-pt2 m-pb3 block_fa784d28c8bcaa2a7d686cb223be2acb  \" style=\"padding-top: 0rem;padding-bottom: 0rem;\">\n    <div class=\"container\">\n\t\t        <div class=\"content\">\n\t\t\t<h2>My\u00e9lome multiple : gestion des soins primaires et r\u00e9f\u00e9rence sur demande<\/h2>\n<p>My\u00e9lome Canada s\u2019est associ\u00e9 \u00e0 l\u2019Universit\u00e9 Queen\u2019s pour offrir un programme de formation m\u00e9dicale accr\u00e9dit\u00e9, accessible sur demande.<\/p>\n<h3>Objectifs d\u2019apprentissage<\/h3>\n<p>\u00c0 la fin de cette formation, vous serez en mesure de :<\/p>\n<ul>\n<li>identifier les signes et sympt\u00f4mes les plus courants d&rsquo;un my\u00e9lome multiple;<\/li>\n<li>\u00e9valuer les patients pr\u00e9sentant des signes et sympt\u00f4mes \u00e9vocateurs d&rsquo;un my\u00e9lome multiple;<\/li>\n<li>r\u00e9f\u00e9rer les patients vers les services appropri\u00e9s, au besoin, en fonction des renseignements cliniques recueillis lors du bilan initial du my\u00e9lome multiple;<\/li>\n<li>discuter du suivi et de la prise en charge des sympt\u00f4mes chez les personnes atteintes d\u2019un my\u00e9lome multiple ou de conditions pr\u00e9curseures.<\/li>\n<\/ul>\n<h3>Accr\u00e9ditation<\/h3>\n<ul>\n<li>5 heures d\u2019autoapprentissage reconnues par le Coll\u00e8ge royal;<\/li>\n<li>5 cr\u00e9dits Mainpro+ dans la cat\u00e9gorie Autoapprentissage du Coll\u00e8ge des m\u00e9decins de famille du Canada;<\/li>\n<li>attestation de 1,5 heure de perfectionnement professionnel pour l\u2019ensemble des professionnels de la sant\u00e9.<\/li>\n<\/ul>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-28324\" src=\"https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/Queens-logo-lockup-healthsciences-profdevedusch-horz-digital-colour-300x63.png\" alt=\"\" width=\"300\" height=\"63\" srcset=\"https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/Queens-logo-lockup-healthsciences-profdevedusch-horz-digital-colour-300x63.png 300w, https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/Queens-logo-lockup-healthsciences-profdevedusch-horz-digital-colour-1024x214.png 1024w, https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/Queens-logo-lockup-healthsciences-profdevedusch-horz-digital-colour-768x160.png 768w, https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/Queens-logo-lockup-healthsciences-profdevedusch-horz-digital-colour-1536x320.png 1536w, https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/Queens-logo-lockup-healthsciences-profdevedusch-horz-digital-colour-2048x427.png 2048w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><br \/>\nL\u2019acc\u00e8s au cours est <strong>sans frais pour les 800 premiers participants<\/strong> gr\u00e2ce au soutien \u00e0 l\u2019apprentissage ind\u00e9pendant de Green for Life, The Binding Site, et Sebia Diagnostics.<\/p>\n<div class=\"lb-button-wrapper\" style=\"text-align: center;\"><div class=\"lb-button-wrapper\"><a class=\"btn btn-filled \" target=\"blank\" href=\"https:\/\/healthsci.queensu.ca\/opdes\/cpd\/educational-programs-opportunities\/cpd\/my%C3%A9lomemultiple\"><span>Acc\u00e9der \u00e0 ce cours gratuit<\/span><\/a><\/div><\/div>\n        <\/div>\n    <\/div>\n<\/div>\n\n\n<div style=\"height:70px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<\/div>\n    <\/div>\n<\/div>\n\n<div data-tab-name=\"Immunoth\u00e9rapie et gestion des effets ind\u00e9sirables\"\n     id=\"immunotherapie-et-gestion-des-effets-indesirables\"\n     class=\"master-tab-block m-pt0  block_545a4171a69b6469215daac5b530e26c\">\n    <div class=\"lm-tab-content\">\n        <div class=\"acf-innerblocks-container\">\n<div class=\" content-1-block m-pt2 m-pb3 block_405501cf98a366aea53ebed4444bc724  \" style=\"padding-top: 0rem;padding-bottom: 0rem;\">\n    <div class=\"container\">\n\t\t        <div class=\"content\">\n\t\t\t<h2>Immunoth\u00e9rapie pour le my\u00e9lome multiple : Principes fondamentaux, prise en charge optimale et collaboration interprofessionnelle (en anglais seulement)<\/h2>\n<p>Cette formation explore les traitements ciblant le BCMA dans le my\u00e9lome multiple en rechute ou r\u00e9fractaire, en abordant les m\u00e9canismes d\u2019action des traitements, la gestion des effets ind\u00e9sirables et la collaboration entre diff\u00e9rents professionnels de la sant\u00e9.<\/p>\n<h3>Accr\u00e9ditation<\/h3>\n<p>Ce programme en ligne comprend deux modules, chacun accr\u00e9dit\u00e9 par l\u2019Universit\u00e9 Queen\u2019s pour 1 heure dans la cat\u00e9gorie d\u2019auto\u00e9valuation (section 3) du Coll\u00e8ge royal, et donnant droit \u00e0 une attestation de 1 heure de perfectionnement professionnel pour l\u2019ensemble des professionnels de la sant\u00e9.<br \/>\n<img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-28324\" src=\"https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/Queens-logo-lockup-healthsciences-profdevedusch-horz-digital-colour-300x63.png\" alt=\"\" width=\"300\" height=\"63\" srcset=\"https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/Queens-logo-lockup-healthsciences-profdevedusch-horz-digital-colour-300x63.png 300w, https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/Queens-logo-lockup-healthsciences-profdevedusch-horz-digital-colour-1024x214.png 1024w, https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/Queens-logo-lockup-healthsciences-profdevedusch-horz-digital-colour-768x160.png 768w, https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/Queens-logo-lockup-healthsciences-profdevedusch-horz-digital-colour-1536x320.png 1536w, https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/Queens-logo-lockup-healthsciences-profdevedusch-horz-digital-colour-2048x427.png 2048w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<div class=\"lb-button-wrapper\" style=\"text-align: center;\"><div class=\"lb-button-wrapper\"><a class=\"btn btn-filled \" target=\"blank\" href=\"https:\/\/healthsci.queensu.ca\/opdes\/cpd\/educational-programs-opportunities\/CPD\/BCMA-MM\"><span>Acc\u00e9der \u00e0 ce cours gratuit (en anglais seulement)<\/span><\/a><\/div><\/div>\n        <\/div>\n    <\/div>\n<\/div>\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n<div class=\" content-1-block m-pt2 m-pb3 block_d96ded87a105e6b0f10df30c7d9e8ec4  \" style=\"padding-top: 4rem;padding-bottom: 4rem;\">\n    <div class=\"container\">\n\t\t        <div class=\"content\">\n\t\t\t<h2>Identification et prise en charge du syndrome de lib\u00e9ration des cytokines et du syndrome de neurotoxicit\u00e9 associ\u00e9e aux cellules effectrices immunitaires (en anglais seulement)<\/h2>\n<p>Identifier les signes pr\u00e9coces, mettre en \u0153uvre des interventions rapides et appropri\u00e9es, et optimiser les soins.<\/p>\n<h3>Accr\u00e9ditation<\/h3>\n<p><strong>Sp\u00e9cialistes du Coll\u00e8ge royal :<\/strong> Ce programme est un programme d\u2019auto\u00e9valuation accr\u00e9dit\u00e9 (section 3), tel que d\u00e9fini par le programme de Maintien du certificat (MDC) du Coll\u00e8ge royal des m\u00e9decins et chirurgiens du Canada, et approuv\u00e9 par l\u2019\u00e9quipe de formation professionnelle continue de l\u2019Universit\u00e9 Queen\u2019s. Vous pouvez r\u00e9clamer un maximum de 0,5 heure.<br \/>\n<strong>Professionnels de la sant\u00e9 : <\/strong>Cette activit\u00e9 de formation professionnelle permet d\u2019obtenir jusqu\u2019\u00e0 0,5 heure de formation continue.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-28324\" src=\"https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/Queens-logo-lockup-healthsciences-profdevedusch-horz-digital-colour-300x63.png\" alt=\"\" width=\"300\" height=\"63\" srcset=\"https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/Queens-logo-lockup-healthsciences-profdevedusch-horz-digital-colour-300x63.png 300w, https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/Queens-logo-lockup-healthsciences-profdevedusch-horz-digital-colour-1024x214.png 1024w, https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/Queens-logo-lockup-healthsciences-profdevedusch-horz-digital-colour-768x160.png 768w, https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/Queens-logo-lockup-healthsciences-profdevedusch-horz-digital-colour-1536x320.png 1536w, https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/Queens-logo-lockup-healthsciences-profdevedusch-horz-digital-colour-2048x427.png 2048w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<div class=\"lb-button-wrapper\" style=\"text-align: center;\"><div class=\"lb-button-wrapper\"><a class=\"btn btn-filled \" target=\"blank\" href=\"https:\/\/healthsci.queensu.ca\/opdes\/cpd\/educational-programs-opportunities\/CRSandICANS\"><span>Acc\u00e9der \u00e0 ce cours gratuit (en anglais seulement)<\/span><\/a><\/div><\/div>\n        <\/div>\n    <\/div>\n<\/div>\n<\/div>\n    <\/div>\n<\/div>\n\n<div data-tab-name=\"Conjugu\u00e9s anticorps-m\u00e9dicaments (CAM)\"\n     id=\"conjugues-anticorps-medicaments-cam\"\n     class=\"master-tab-block m-pt0  block_e82b08f3b242b6690d4918e9c7a89307\">\n    <div class=\"lm-tab-content\">\n        <div class=\"acf-innerblocks-container\">\n<div class=\" content-1-block m-pt2 m-pb3 block_9139f520222338b6486f63442757f16f  \" style=\"padding-top: 0rem;padding-bottom: 0rem;\">\n    <div class=\"container\">\n\t\t        <div class=\"content\">\n\t\t\t<h2>A.C.T. I.O.N en my\u00e9lome: Raisonnement clinique appliqu\u00e9 en oncologie<\/h2>\n<p>Ce programme d\u2019une heure, offert en fran\u00e7ais et en anglais, et destin\u00e9 aux pharmaciens et au personnel infirmier, met l\u2019accent sur l\u2019optimisation de la prise en charge des effets ind\u00e9sirables oculaires et sur l\u2019accompagnement des patients recevant un traitement par conjugu\u00e9s anticorps-m\u00e9dicament (CAM) pour un my\u00e9lome multiple en rechute ou r\u00e9fractaire.<\/p>\n<h3>Objectifs d\u2019apprentissage<\/h3>\n<ul>\n<li>Partager des perspectives issues de la pratique sur les facteurs qui influencent la prise de d\u00e9cision entourant le d\u00e9but de nouveaux traitements du my\u00e9lome.<\/li>\n<li>Appliquer des consid\u00e9rations pratiques li\u00e9es \u00e0 la posologie et \u00e0 l\u2019administration de nouveaux traitements anti-BCMA, notamment les CAM, afin de favoriser une prise en charge fond\u00e9e sur des donn\u00e9es probantes et centr\u00e9e sur le patient.<\/li>\n<li>Montrer comment optimiser la collaboration avec les autres professionnels de la sant\u00e9, en mettant l\u2019accent sur la prise en charge des effets ind\u00e9sirables.<\/li>\n<\/ul>\n<h3>Accr\u00e9ditation<\/h3>\n<ul>\n<li>Le Conseil canadien de la formation continue en pharmacie (CCFCP) a accr\u00e9dit\u00e9 ce programme pour 1,75 UEC.<\/li>\n<li>L\u2019Association des infirmi\u00e8res et infirmiers du Canada (AIIC) a accr\u00e9dit\u00e9 ce programme pour 1,00 UEC.<\/li>\n<\/ul>\n<div class=\"lb-button-wrapper\" style=\"text-align: center;\"><div class=\"lb-button-wrapper\"><a class=\"btn btn-filled \" target=\"blank\" href=\"https:\/\/meducomhealth.swoogo.com\/actioninmyeloma-ondemand\/10779649?reg_type_id=1168669&amp;lang=fr\"><span>Acc\u00e9der \u00e0 ce cours gratuit<\/span><\/a><\/div><\/div>\n        <\/div>\n    <\/div>\n<\/div>\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n<div class=\" content-1-block m-pt2 m-pb3 block_07d4aa5794b2d521d988439c8a9da3db  \" style=\"padding-top: 4rem;padding-bottom: 4rem;\">\n    <div class=\"container\">\n\t\t        <div class=\"content\">\n\t\t\t<h2>mEYEloma : Le r\u00f4le des professionnels de la sant\u00e9 oculaire dans la prise en charge des effets ind\u00e9sirables des traitements en oncologie<\/h2>\n<p>Identifier les signes pr\u00e9coces, mettre en \u0153uvre des interventions rapides et appropri\u00e9es, et optimiser les soins.<br \/>\nCe programme de 45 minutes, accessible sur demande et destin\u00e9 aux professionnels de la sant\u00e9 oculaire, porte sur les effets ind\u00e9sirables pouvant affecter les yeux, associ\u00e9s \u00e0 un nouveau traitement du my\u00e9lome multiple.<\/p>\n<h3>Objectifs d\u2019apprentissage<\/h3>\n<p>\u00c0 la fin de cette formation, les participants seront en mesure de :<\/p>\n<ul>\n<li>revoir les traitements anticanc\u00e9reux et les effets ind\u00e9sirables oculaires associ\u00e9s aux conjugu\u00e9s anticorps-m\u00e9dicaments (CAM);<\/li>\n<li>identifier et prendre en charge ces effets ind\u00e9sirables li\u00e9s aux CAM gr\u00e2ce \u00e0 une prise de d\u00e9cision collaborative et \u00e0 l\u2019analyse de cas patients;<\/li>\n<li>diff\u00e9rencier les r\u00f4les des professionnels de la sant\u00e9 oculaire et des oncologues dans la prise en charge de ces effets ind\u00e9sirables et favoriser une collaboration interdisciplinaire efficace.<\/li>\n<\/ul>\n<h3>Accr\u00e9ditation<\/h3>\n<p>Ce programme a \u00e9t\u00e9 accr\u00e9dit\u00e9 par le Council on Optometric Practitioner Education (COPE) pour 1,00 heure de cr\u00e9dit.<\/p>\n<div class=\"lb-button-wrapper\" style=\"text-align: center;\"><div class=\"lb-button-wrapper\"><a class=\"btn btn-filled \" target=\"blank\" href=\"https:\/\/meducomhealth.swoogo.com\/meyeloma-asynchronouswebinar\/10295708?reg_type_id=1168673&amp;lang=fr\"><span>Acc\u00e9der \u00e0 ce cours gratuit<\/span><\/a><\/div><\/div>\n        <\/div>\n    <\/div>\n<\/div>\n<\/div>\n    <\/div>\n<\/div>\n\n<div data-tab-name=\"Modules d\u2019auto\u00e9valuation\"\n     id=\"modules-dautoevaluation\"\n     class=\"master-tab-block m-pt0  block_ab4dbc17dd32fcd0f7b3ef605ad4ebf1\">\n    <div class=\"lm-tab-content\">\n        <div class=\"acf-innerblocks-container\">\n<div class=\" content-1-block m-pt2 m-pb3 block_a6a1cf273a9ff50b00b22f1945c88a58  \" style=\"padding-top: 0rem;padding-bottom: 0rem;\">\n    <div class=\"container\">\n\t\t        <div class=\"content\">\n\t\t\t<p>Les modules d\u2019auto\u00e9valuation sont con\u00e7us pour renforcer les notions cl\u00e9s li\u00e9es au diagnostic, au suivi et \u00e0 la prise en charge du my\u00e9lome multiple. Ils peuvent \u00eatre suivis \u00e0 tout moment et s\u2019adressent \u00e0 l\u2019ensemble des professionnels de la sant\u00e9 impliqu\u00e9s dans les soins du my\u00e9lome.<\/p>\n<h2>My\u00e9lome multiple : auto\u00e9valuation des lignes directrices consensuelles<\/h2>\n<p>My\u00e9lome Canada s\u2019est associ\u00e9 \u00e0 l\u2019Universit\u00e9 Queen\u2019s pour offrir un programme de formation m\u00e9dicale accr\u00e9dit\u00e9, accessible sur demande.<\/p>\n<p>Dans le cadre de ce programme, vous serez invit\u00e9(e) \u00e0 :<\/p>\n<ul>\n<li>examiner un ou plusieurs documents de consensus \u00e9labor\u00e9s par un consortium canadien de lignes directrices, dirig\u00e9 par My\u00e9lome Canada;<\/li>\n<li>auto\u00e9valuer votre pratique et vos connaissances en les comparant aux lignes directrices de r\u00e9f\u00e9rence;<\/li>\n<li>r\u00e9pondre \u00e0 une s\u00e9rie de questions d\u2019\u00e9valuation des connaissances, accompagn\u00e9es d\u2019une r\u00e9troaction visant \u00e0 orienter d\u2019\u00e9ventuels ajustements \u00e0 votre pratique clinique.<\/li>\n<\/ul>\n<p>Le Comit\u00e9 de planification scientifique tient \u00e0 remercier Apotex Canada pour son g\u00e9n\u00e9reux soutien sous forme de subvention ind\u00e9pendante en formation m\u00e9dicale.<\/p>\n<h3>Accr\u00e9ditation<\/h3>\n<p>Ce programme de formation est une activit\u00e9 d\u2019auto\u00e9valuation guid\u00e9e qui donne droit \u00e0 des cr\u00e9dits de la section 3 (auto\u00e9valuation) du Coll\u00e8ge royal, ainsi qu\u2019\u00e0 des cr\u00e9dits Mainpro+ d\u2019\u00e9valuation certifi\u00e9e, tels que d\u00e9finis par le Coll\u00e8ge des m\u00e9decins de famille du Canada.<\/p>\n<div class=\"lb-button-wrapper\" style=\"text-align: center;\"><div class=\"lb-button-wrapper\"><a class=\"btn btn-filled \" target=\"blank\" href=\"https:\/\/queensu.qualtrics.com\/jfe\/form\/SV_41vhD6HLTu3wEhE\"><span>Acc\u00e9der \u00e0 ce programme gratuit<\/span><\/a><\/div><\/div>\n        <\/div>\n    <\/div>\n<\/div>\n<\/div>\n    <\/div>\n<\/div>\n\n<div data-tab-name=\"Outils cliniques\"\n     id=\"outils-cliniques\"\n     class=\"master-tab-block m-pt0  block_faa947aef2c07f171fd39bc21631a25c\">\n    <div class=\"lm-tab-content\">\n        <div class=\"acf-innerblocks-container\">\n<div class=\" content-1-block m-pt2 m-pb3 block_c5b3cb9fa0026c5649936bd24c46d3d1  \" style=\"padding-top: 0rem;padding-bottom: 0rem;\">\n    <div class=\"container\">\n\t\t        <div class=\"content\">\n\t\t\t<p>Cette section contient des ressources pratiques t\u00e9l\u00e9chargeables visant \u00e0 soutenir la prise de d\u00e9cision clinique, l\u2019identification des effets ind\u00e9sirables, la posologie, le suivi et la prise en charge coordonn\u00e9e.<\/p>\n<h2>Utilisation du b\u00e9lantamab mafodotin pour le traitement du my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire<\/h2>\n<p><a href=\"https:\/\/www.canadiankt.org\/multiple-myeloma\" target=\"_blank\" rel=\"noopener\">Le <em>Canadian Institute for the Transfer of Knowledge<\/em> (CITE)<\/a> a \u00e9labor\u00e9 des lignes directrices cliniques pr\u00e9sentant des recommandations pratiques pour l\u2019utilisation s\u00e9curitaire et efficace du b\u00e9lantamab mafodotin chez les adultes atteints d\u2019un my\u00e9lome multiple en rechute ou r\u00e9fractaire. Ce document comprend des consid\u00e9rations li\u00e9es \u00e0 la posologie, \u00e0 la surveillance des effets ind\u00e9sirables oculaires, aux strat\u00e9gies d\u2019ajustement de la dose ainsi qu\u2019aux mesures de soutien visant \u00e0 r\u00e9duire les complications li\u00e9es au traitement.<\/p>\n<div class=\"lb-button-wrapper\" style=\"text-align: center;\"><div class=\"lb-button-wrapper\"><a class=\"btn btn-filled \" target=\"blank\" href=\"https:\/\/www.canadiankt.org\/_files\/ugd\/9f0189_f59f1eeb213446028502f25f94a29e5e.pdf\"><span>T\u00e9l\u00e9charger l&rsquo;outil clinique<\/span><\/a><\/div><\/div>\n<div class=\"lb-button-wrapper\" style=\"text-align: center;\"><div class=\"lb-button-wrapper\"><a class=\"btn-with-icon \" target=\"blank\" href=\"https:\/\/www.canadiankt.org\/_files\/ugd\/9f0189_ece3d1cdb2074db09d108c390456bd6d.pdf\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" width=\"20\" height=\"20\" viewBox=\"0 0 20 20\"> <g transform=\"translate(-406 -2843)\"> <circle cx=\"10\" cy=\"10\" r=\"10\" transform=\"translate(406 2843)\" fill=\"#1c596c\"\/> <g transform=\"translate(412.135 2845)\"> <g transform=\"translate(10.732 7.866) rotate(135)\"> <path d=\"M0,4.968V0H4.968\" transform=\"translate(3.389 2.774)\" fill=\"none\" stroke=\"#fff\" stroke-linecap=\"round\" stroke-miterlimit=\"10\" stroke-width=\"1\"\/> <\/g> <\/g> <\/g> <\/svg><span>T\u00e9l\u00e9charger l&rsquo;outil clinique en anglais<\/span><\/a><\/div><\/div>\n        <\/div>\n    <\/div>\n<\/div>\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n<div class=\" content-1-block m-pt2 m-pb3 block_a7481c78afc288a7e281f0581be3675c  \" style=\"padding-top: 4rem;padding-bottom: 4rem;\">\n    <div class=\"container\">\n\t\t        <div class=\"content\">\n\t\t\t<h2>Utilisation des anticorps bisp\u00e9cifiques ciblant les lymphocytes T pour le traitement du my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire (en anglais)<\/h2>\n<p><a href=\"https:\/\/www.canadiankt.org\/multiple-myeloma\" target=\"_blank\" rel=\"noopener\">Le <em>Canadian Institute for the Transfer of Knowledge<\/em> (CITE)<\/a> a \u00e9labor\u00e9 des directives cliniques pour soutenir l&rsquo;utilisation s\u00e9curitaire et efficace des anticorps bisp\u00e9cifiques ciblant les lymphocytes T chez les adultes atteints d&rsquo;un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire. Ce document pr\u00e9sente des recommandations pratiques concernant l&rsquo;augmentation progressive de la posologie, les modalit\u00e9s de reprise du traitement apr\u00e8s une interruption, la prophylaxie des infections, la surveillance des taux d\u2019immunoglobulines ainsi que les strat\u00e9gies de soins de soutien. Il comprend \u00e9galement des algorithmes pour l\u2019identification et la prise en charge du syndrome de lib\u00e9ration des cytokines et du syndrome de neurotoxicit\u00e9 associ\u00e9e aux cellules effectrices immunitaires, afin d&rsquo;aider l&rsquo;\u00e9quipe soignante \u00e0 intervenir rapidement et de fa\u00e7on appropri\u00e9e.<\/p>\n<div class=\"lb-button-wrapper\" style=\"text-align: center;\"><div class=\"lb-button-wrapper\"><a class=\"btn btn-filled \" target=\"blank\" href=\"https:\/\/www.canadiankt.org\/_files\/ugd\/9f0189_0004dd8b8a9f44c09ff7ea51dbbb6c0e.pdf\"><span>T\u00e9l\u00e9charger l&rsquo;outil clinique (en anglais seulement)<\/span><\/a><\/div><\/div>\n        <\/div>\n    <\/div>\n<\/div>\n<\/div>\n    <\/div>\n<\/div>\n\n<div data-tab-name=\"\u00c9v\u00e9nements\"\n     id=\"evenements\"\n     class=\"master-tab-block m-pt0  block_36f68c187698da09165678e2dafc0df9\">\n    <div class=\"lm-tab-content\">\n        <div class=\"acf-innerblocks-container\">\n<div class=\" content-1-block m-pt2 m-pb3 block_9bc86048fefb0e62322594ee5c4cf0da  \" style=\"padding-top: 0rem;padding-bottom: 0rem;\">\n    <div class=\"container\">\n\t\t        <div class=\"content\">\n\t\t\t<p>Cette section pr\u00e9sente des \u00e9v\u00e9nements \u00e9ducatifs offrant des mises \u00e0 jour pertinentes aux professionnels de la sant\u00e9 impliqu\u00e9s dans les soins des personnes atteintes d&rsquo;un my\u00e9lome multiple.<\/p>\n<h2>Journ\u00e9e du my\u00e9lome multiple du Princess Margaret Cancer Centre (en anglais seulement)<\/h2>\n<p>La Journ\u00e9e du my\u00e9lome multiple du Princess Margaret Cancer Centre pr\u00e9sente les derni\u00e8res avanc\u00e9es dans la prise en charge du my\u00e9lome et des troubles plasmocytaires connexes.<br \/>\n<strong>Date:<\/strong> 22 mai 2026<br \/>\n<strong>Heure:<\/strong> 8 h \u00e0 14 h 15<br \/>\n<strong>Lieu: <\/strong>The Estates of Sunnybrook, 135 Armistice Drive, North York (Ontario) M4N 1J8<br \/>\n<strong>Public cible<\/strong><br \/>\nCe programme sera utile aux professionnels de la sant\u00e9 en milieu communautaire, notamment aux m\u00e9decins, aux infirmi\u00e8res, aux pharmaciens, aux stagiaires et \u00e0 d\u2019autres professionnels de la sant\u00e9 qui prennent en charge des patients atteints de troubles des plasmocytes.<\/p>\n<div class=\"lb-button-wrapper\" style=\"text-align: center;\"><div class=\"lb-button-wrapper\"><a class=\"btn btn-filled \" target=\"blank\" href=\"https:\/\/www.cpd.utoronto.ca\/myeloma\/\"><span>Plus d&rsquo;informations<\/span><\/a><\/div><\/div>\n        <\/div>\n    <\/div>\n<\/div>\n<\/div>\n    <\/div>\n<\/div>\n<\/div>\n\n            <nav class=\"master-page-anchor-wrapper\">\n            <div class=\"master-page-anchor-header\">\n                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24.054\" height=\"33.63\" viewBox=\"0 0 24.054 33.63\"><path d=\"M195.2,91.649h16a4.033,4.033,0,0,0,4.029-4.029V69.084a.588.588,0,0,0-.106-.348l-.047-.042-.055-.064L204.1,58.185a.594.594,0,0,0-.42-.165H195.2a4.033,4.033,0,0,0-4.029,4.029V87.62A4.033,4.033,0,0,0,195.2,91.65Zm9.088-31.518,8.715,8.316h-7.633a1.06,1.06,0,0,1-1.06-1.06ZM192.448,62.04h0a2.761,2.761,0,0,1,2.756-2.757h7.816v8.1a2.336,2.336,0,0,0,2.332,2.332h8.6v17.9a2.761,2.761,0,0,1-2.756,2.757h-16a2.761,2.761,0,0,1-2.756-2.757Z\" transform=\"translate(-191.175 -58.02)\" fill=\"#fff\"\/><\/svg>\n                <span>Sur cette page<\/span>\n                <button class=\"master-page-anchor-toggler\" type=\"button\"><i class=\"fa-solid fa-chevrons-left\"><\/i><\/button>\n            <\/div>\n            <div class=\"master-page-anchor-hiddable\">\n                <div class=\"master-page-anchor-navigation\">\n\n                <\/div>\n                <div class=\"master-page-anchor-footer\">\n                    <a href=\"#\" class=\"back-to-top\">\n                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" width=\"20\" height=\"20\" viewBox=\"0 0 20 20\"><g transform=\"translate(-2843 426) rotate(-90)\"><circle cx=\"10\" cy=\"10\" r=\"10\" transform=\"translate(406 2843)\" fill=\"#1c596c\"\/><g transform=\"translate(412.135 2845)\"><g transform=\"translate(10.732 7.866) rotate(135)\"><path d=\"M0,4.968V0H4.968\" transform=\"translate(3.389 2.774)\" fill=\"none\" stroke=\"#fff\" stroke-linecap=\"round\" stroke-miterlimit=\"10\" stroke-width=\"1\"\/><\/g><\/g><\/g><\/svg>\n                        <span>Retour en haut<\/span>\n                    <\/a>\n                <\/div>\n            <\/div>\n        <\/nav>\n    \n<\/div>\n\n\n<div style=\"height:70px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":10,"featured_media":0,"parent":19731,"menu_order":152,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"tags":[],"class_list":["post-28350","page","type-page","status-publish","hentry"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/pages\/28350","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=28350"}],"version-history":[{"count":20,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/pages\/28350\/revisions"}],"predecessor-version":[{"id":33491,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/pages\/28350\/revisions\/33491"}],"up":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/pages\/19731"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=28350"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=28350"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}